CombiGene discontinues the preclinical development of the lipodystrophy project CGT2
February 1, 2024
CombiGene AB (publ) (“CombiGene”, the “Company”) today announces that the Company has decided to discontinue the
CombiGene AB (publ) (“CombiGene”, the “Company”) today announces that the Company has decided to discontinue the
CombiGene AB (publ) (“CombiGene”, “the Company”) today announces that the Company has regained the global rights
CombiGene AB (publ) (“CombiGene”, the “Company”) today announces that the peptide-based pain project COZY01 receives Eurostars
Read CombiGene’s newsletter in English here. Ingeneious issue no 5 2023 mobile friendly Contacts CombiGene AB
CombiGene AB (publ) (“CombiGene”, the “Company”) today announces that the Company, after a thorough evaluation process,
CombiGene and Zyneyro, together with, among others, the pain program COZY’s Scientific Advisory Board, have analyzed
The nominating committee has been constituted in accordance with the resolution adopted by the annual general
CombiGene today announces that the company will regain the global rights for the epilepsy project CG01
CombiGene AB (publ) (“CombiGene”, the “Company”) today announces that the Company, after a thorough evaluation process,
Read CombiGene’s newsletter in English here or download the attachment. Ingeneious issue no 4 2023 mobile